
package-statement:
  id: PS-MammaOnco
  title: Standpunt ‘Genexpressietesten bij vrouwen ouder dan 50 jaar en vroeg stadium borstkanker’
  date: 2023-10-24
  package-type: PointOfView
  case-number: 2022006448
  serial-number: 2022006461
  status: Definitive
  contact-person: [Ingrid de Groot,Angèl Link,Steef Redeker,Yoka Kusumanto]
  department: Zorg 1
  team: Pakket en Advies
  see-also: "https://www.zorginstituutnederland.nl/documenten/2023/10/24/standpunt---mammaprint-en-oncotype-dx-vergoede-zorg-voor-bepaalde-groep-vrouwen"
  iic-assessments:
  - IICAssessment-MammaPrint
  - IICAssessment-OncotypeDX

populations:
  - id: Population-WomenBreastCancer50plusHRplusHERminN0
    title: Vrouwen ouder dan 50 met borstkanker, HR+/HER2-, N0, hoog risico op basis van AO! of Predict
    sex: Female
    age: Age more than 50 years
    conditions:
      - Breast Cancer
      - Estrogen Receptor Positive Tumor
      - Progesterone Receptor Positive Tumor
      - Human Epidermal Growth Factor 2 Negative Carcinoma Of Breast
      - N0 Category
      # - G1 Grade
      # - Tumor size between 3.1 cm and 5.0 cm
      - High risk based on AO! or Predict
    treatment: [Surgery]
  - id: Population-WomenBreastCancer50plusHRplusHERminN1
    title: Vrouwen ouder dan 50 met borstkanker, HR+/HER2-, N1, hoog risico op basis van AO! of Predict
    sex: Female
    age: Age more than 50 years
    conditions:
      - Breast Cancer
      - Estrogen Receptor Positive Tumor
      - Progesterone Receptor Positive Tumor
      - Human Epidermal Growth Factor 2 Negative Carcinoma Of Breast
      - N1 Category
      # - G1 Grade
      # - Tumor size between 3.1 cm and 5.0 cm
      - High risk based on AO! or Predict
    treatment: [Surgery]

interventions:
  # TODO: Add Dutch title
  - id: Intervention-MammaPrint
    title: Complexe moleculaire diagnostiek genexpressietest op basis van 70 genen, MammaPrint®
    applied-intervention: MammaPrint
    intervention-rationale: Ondersteunt beslissing om chemotherapie achterwege te laten
    intervention-classification: Screening
    marketing-authorization-holder: Agendia
    claim-code: 1602
    care-activity-code: "050530"
    costs: 3_249
  - id: Intervention-OncotypeDX
    title: Complexe moleculaire diagnostiek genexpressietest op basis van 21 genen, Oncotype DX®
    applied-intervention: OncotypeDX
    intervention-rationale: Ondersteunt beslissing om chemotherapie achterwege te laten
    intervention-classification: Screening
    marketing-authorization-holder: Exact Sciences
    claim-code: 2601
    care-activity-code: "050531"
    costs: 4_832
  - id: Intervention-PostoperativeChemo
    title: Postoperatieve Chemotherapie
    applied-intervention: Postoperative chemotherapy
    intervention-rationale: behandeling van afstandsmetastasen na chirurgie
    intervention-classification: Pharmacological Interventions
    cost: 15_809
  - id: Intervention-MammaPrint-Chemo
    title: Chemotherapie op basis van MammaPrint uitslag
    applied-intervention: Genetic test adviced Chemotherapy
    intervention-rationale: Pas chemotherapie toe naar aanleiding van hoge risicoschatting MammaPrint
    intervention-classification: Screening
    child-interventions:
    - Intervention-MammaPrint
    - Intervention-PostoperativeChemo
    costs: 19_058  # 3249 + 15809
  - id: Intervention-OncotypeDX-Chemo
    title: Chemotherapie op basis van Oncotype DX uitslag
    applied-intervention: Genetic test adviced Chemotherapy
    intervention-rationale: Pas chemotherapie toe naar aanleiding van hoge risicoschatting Oncotype DX
    intervention-classification: Screening
    child-interventions:
    - Intervention-OncotypeDX
    - Intervention-PostoperativeChemo
    costs: 20_641  # 4832 + 15809

intervention-groups:
  - id: InterventionGroup-MammaOnco-Intervention
    title: MammaPrint/Oncotype DX Interventiegroep
    intervention-ids: [Intervention-MammaPrint-Chemo, Intervention-OncotypeDX-Chemo]
  - id: InterventionGroup-MammaOnco-Comparator
    title: Standaard zorg groep
    intervention-ids: [Intervention-PostoperativeChemo]

outcomes:
  # MammaOnco
  - id: Outcome-Overall-Survival
    name: Overall Survival
    outcome-classification: Survival
    outcome-measurement: Overall Survival
    surrogate-outcome: False
  - id: Outcome-FACT-B
    name: Functional Assessment of Cancer Therapy - Breast (FACT-B)
    outcome-classification: Quality of Life
    outcome-measurement: Functional Assessment of Cancer Therapy
    surrogate-outcome: False
  - id: Outcome-EORTC-QLQ-C30
    name: European Organization For Research And Treatment Of Cancer - Quality Of Life Questionnaire (EORTC QLQ-C30)
    outcome-classification: Quality of Life
    outcome-measurement: European Organization For Research And Treatment Of Cancer - Quality Of Life Questionnaire (EORTC QLQ-C30)
    surrogate-outcome: False
  - id: Outcome-EQ-5D-5L
    name: EQ-5D-5L - Quality of Life
    outcome-classification: Quality of Life
    outcome-measurement: EQ-5D-5L
    surrogate-outcome: False
  # Not from PICO, but needed for outcome measurements:
  - id: Outcome-Invasive-Disease-Free-Survival
    name: Invasive Disease-Free Survival
    outcome-classification: Survival
    outcome-measurement: Invasive Disease-Free Survival
    surrogate-outcome: True
  - id: Outcome-Distant-Relapse-Free-Survival
    name: Distant Relapse-Free Survival
    outcome-classification: Survival
    outcome-measurement: Distant Relapse-Free Survival
    surrogate-outcome: True

outcome-groups:
  - id: OutcomeGroup-MammaOnco-10-years
    endpoint: 10 years or more
    outcome-ids:
    - Outcome-Overall-Survival
    - Outcome-FACT-B
    - Outcome-EORTC-QLQ-C30
    - Outcome-EQ-5D-5L

picots:
  - id: PICO-MammaOnco
    population-ids:
    - Population-WomenBreastCancer50plusHRplusHERminN0
    - Population-WomenBreastCancer50plusHRplusHERminN1
    intervention-group-id: InterventionGroup-MammaOnco-Intervention
    comparator-group-id: InterventionGroup-MammaOnco-Comparator
    outcome-group-ids: [OutcomeGroup-MammaOnco-10-years]

intervention-indication-combination-assessments:
  - id: IICAssessment-MammaPrint
    assessment-type: Reassessment
    intervention-id: Intervention-MammaPrint
    indication-ids:
    - Population-WomenBreastCancer50plusHRplusHERminN0
    - Population-WomenBreastCancer50plusHRplusHERminN1
    emsmp-id: EMSMP-MammaPrint
    bia-id: BIA-MammaPrint
    au-id: AU-MammaOnco
    conclusion: Positive
    conclusion-text: "Het Zorginstituut concludeert dat de genexpressietest Oncotype DX® en de genexpressietest MammaPrint® bij de genoemde indicaties voldoet aan ‘de stand van de wetenschap en praktijk’ en daarmee bij deze subgroep van vrouwen vergoed kan worden vanuit de basisverzekering."
    cost-effective: True
  - id: IICAssessment-OncotypeDX
    assessment-type: Indication broadening
    intervention-id: Intervention-OncotypeDX
    indication-ids:
    - Population-WomenBreastCancer50plusHRplusHERminN1
    emsmp-id: EMSMP-OncotypeDX
    bia-id: BIA-OncotypeDX
    au-id: AU-MammaOnco
    conclusion: Positive
    conclusion-text: "Het Zorginstituut concludeert dat de genexpressietest Oncotype DX® en de genexpressietest MammaPrint® bij de genoemde indicaties voldoet aan ‘de stand van de wetenschap en praktijk’ en daarmee bij deze subgroep van vrouwen vergoed kan worden vanuit de basisverzekering."
    cost-effective: True

emsmps: # Established Medical Science and Medical Practice
  - id: EMSMP-MammaPrint
    title: Stand van de Wetenschap en Praktijk - MammaPrint
    picots-id: PICO-MammaOnco
    slr-id: SLR-MammaOnco
    outcome-measurement-ids:
    - OutcomeMeasurement-OverallSurvival-TTI-AbsoluteDifference-MammaPrint
    - OutcomeMeasurement-OverallSurvival-TTI-HazardRatio-MammaPrint
    - OutcomeMeasurement-OverallSurvival-PP-AbsoluteDifference-MammaPrint
    - OutcomeMeasurement-OverallSurvival-PP-HazardRatio-MammaPrint
    relative-effectiveness: Equal
    adheres-to-emsmps: True
  - id: EMSMP-OncotypeDX
    title: Stand van de Wetenschap en Praktijk - OncotypeDX
    picots-id: PICO-MammaOnco
    slr-id: SLR-MammaOnco
    outcome-measurement-ids:
    - OutcomeMeasurement-Distant-Relapse-Free-Survival-ITT-HazardRatio-OncotypeDX
    - OutcomeMeasurement-Distant-Relapse-Free-Survival-ITT-AbsoluteDifference-OncotypeDX
    - OutcomeMeasurement-Invasive-Disease-Free-Survival-ITT-HazardRatio-OncotypeDX
    - OutcomeMeasurement-Invasive-Disease-Free-Survival-ITT-AbsoluteDifference-OncotypeDX
    - OutcomeMeasurement-Invasive-Disease-Free-Survival-PP-HazardRatio-OncotypeDX
    - OutcomeMeasurement-Invasive-Disease-Free-Survival-PP-AbsoluteDifference-OncotypeDX
    relative-effectiveness: Equal
    adheres-to-emsmps: True
    cost-effective: True

systematic-literature-reviews: # SLR
  - id: SLR-MammaOnco
    title: Systematisch literatuuronderzoek MammaPrint/Oncotype DX
    literature-searches: 
    - LS-MammaOnco-Embase-2022-10-26
    - LS-MammaOnco-Medline-2-2022-10-26
    - LS-MammaOnco-ClinicaltrialsGov-2022-11-01
    - LS-ICTRP-SearchPortal-2022-11-01
    - LS-MammaOnco-Cochrane-2022-11-01
    literature-reference-list: LRL-MammaOnco

literature-searches:
  - id: LS-MammaOnco-Embase-2022-10-26
    label: Literatuur zoekopdracht voor MammaPrint en Oncotype DX in Embase op 2022-10-26
    end-time: 2022-10-26T00:00:00
    target-db: Embase
    target-url: https://www.embase.com/
    evidence-type: 
    query: >-
      ((mammaprint* OR 70-gene* OR MINDACT OR oncotype* OR 21-gene*):ab,ti,kw) AND ('breast tumor'/exp OR (((breast*) NEAR/3 (tumor* OR tumour* OR neoplas* OR carcino* OR cancer*))):ab,ti,kw) AND [2018-2023]/py NOT ([Conference Abstract]/lim OR 'editorial'/it OR 'letter'/it OR 'note'/it OR 'chapter'/it OR 'conference abstract'/it OR 'conference paper'/it OR 'conference review'/it OR 'erratum'/it OR [preprint]/lim) NOT ((animal/exp OR animal*:de OR nonhuman/de) NOT ('human'/exp)) AND ('clinical study'/de OR 'clinical trial'/exp OR 'intervention study'/exp OR 'longitudinal study'/exp OR 'prospective study'/exp OR (((clinical OR prospect* OR intervention* OR longitudinal* OR randomi*) NEAR/3 (stud* OR trial*))):ab,ti)
  - id: LS-MammaOnco-Medline-2-2022-10-26
    label: Literatuur zoekopdracht voor MammaPrint en Oncotype DX in Medline op 2022-10-26
    end-time: 2022-10-26T00:00:00
    target-db: Medline
    target-url: https://www.medline.com/
    evidence-type:
    query: >-
      ((mammaprint* OR 70-gene* OR MINDACT OR oncotype* OR 21-gene*).ab,ti,kf.) AND (exp "Breast Neoplasms"/ OR (((breast*) ADJ3 (tumor* OR tumour* OR neoplas* OR carcino* Or cancer*))).ab,ti,kf.) AND ("Clinical Study".pt OR "Clinical Trial".pt OR "Controlled Clinical Trial".pt. OR "Randomized Controlled Trial".pt. OR "Longitudinal Studies"/ OR "Prospective Studies"/ OR (((clinical OR prospect* OR intervention* OR longitudinal* OR randomi*) ADJ3 (stud* OR trial*))).ab,ti,kf.) NOT ("Editorial".pt. OR "Comment".pt. OR "Letter".pt. OR "News".pt. OR "Congress".pt. OR "Meeting Abstract".pt. OR "Abstracts".pt. OR "Academic Dissertation".pt. OR "Published Erratum".pt. OR (book* OR chapter* OR dissertation abstract*).pt.) NOT (exp animals/ NOT humans/)
    range-beginning: 2017
    range-end: 2023
  - id: LS-MammaOnco-ClinicaltrialsGov-2022-11-01
    label: Literatuur zoekopdracht voor RCTs op MammaPrint en Oncotype DX in Clinicaltrials.gov op 2022-10-26
    end-time: 2022-11-01T00:00:00
    target-db: Clinicaltrials.gov
    target-url: https://clinicaltrials.gov/
    evidence-type: Clinical Trial
    query: >-
      (mammaprint OR oncotype) AND breast AND (cancer OR carcinoma OR tumor OR tumour OR neoplasm)
  - id: LS-ICTRP-SearchPortal-2022-11-01
    label: Literatuur zoekopdracht voor RCTs op MammaPrint en Oncotype DX in ICTRP Search Portal (WHO) op 2022-11-01
    end-time: 2022-11-01T00:00:00
    target-db: ICTRP Search Portal
    target-url: https://trialsearch.who.int/
    evidence-type: Clinical Trial
    query: >-
      (mammaprint OR oncotype) AND breast AND (cancer OR carcinoma OR tumor OR tumour OR neoplasm)
  - id: LS-MammaOnco-Cochrane-2022-11-01
    label: Literatuur zoekopdracht voor RCTs op MammaPrint en Oncotype DX in Cochrane op 2022-11-01
    end-time: 2022-11-01T00:00:00
    target-db: Cochrane
    target-url: https://www.cochranelibrary.com/
    evidence-type: Clinical Trial
    query: >-
      (mammaprint OR oncotype):ab,ti AND (breast NEXT/2 (cancer OR carcino* OR tumor* OR tumour* OR neoplas*)):ab,ti

publications:
  - id: JournalArticle-MINDACT
    type: JournalArticle
    title: "70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age."
    authors: [Piccart M, van 't Veer LJ, Poncet C, Lopes Cardozo JMN, Delaloge S, Pierga JY, Vuylsteke P, Brain E, Vrijaldenhoven S, Neijenhuis PA, Causeret S, Smilde TJ, Viale G, Glas AM, Delorenzi M, Sotiriou C, Rubio IT, Kümmel S, Zoppoli G, Thompson AM, Matos E, Zaman K, Hilbers F, Fumagalli D, Ravdin P, Knox S, Tryfonidis K, Peric A, Meulemans B, Bogaerts J, Cardoso F, Rutgers EJT]
    journal: The Lancet, Oncology
    year: 2021
    issue: 22
    pages: 476-88
  - id: JournalArticle-RxPONDER
    type: JournalArticle
    title: "21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer"
    authors: [Kalinsky K, Barlow WE, Gralow JR, Meric‐Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Chia SKL, Dhesy‐Thind S, Rastogi P, Alba E, Delaloge S, Martin M, Kelly CM, Ruiz‐Borrego M, Gil‐Gil M, Arce‐Salinas CH, Brain EGC, Lee ES, Pierga JY, Bermejo B, Ramos‐Vazquez M, Jung KH, Ferrero JM, Schott AF, Shak S, Sharma P, Lew DL, Miao J, Tripathy D, Pusztai L, Hortobagyi GN]
    journal: New England journal of medicine
    year: 2021
    issue: 385
    pages: 2336‐2347

literature-reference-lists:
  - id: LRL-MammaOnco
    title: Literatuur referentielijst voor MammaPrint en Oncotype DX SLR
    number-of-items: 2
    references:
    - JournalArticle-MINDACT
    - JournalArticle-RxPONDER
  
studies:
  - id: Study-MINDACT
    title: "Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes (MINDACT)"
    short-title: MINDACT
    registry: Clinicaltrials.gov
    registry-id: NCT00433589
    start-date: 2007-03
    end-date: 2020-03
    study-type: Interventional
    phase: Phase 3
    sponsor: European Organisation for Research and Treatment of Cancer - EORTC
    url: https://clinicaltrials.gov/study/NCT00433589
    publication-ids:
    - JournalArticle-MINDACT
  - id: Study-RxPONDER
    title: "Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer"
    short-title: RxPONDER
    registry: Clinicaltrials.gov
    registry-id: NCT01272037
    start-date: 2011-01-15
    end-date: 2023-02-01
    study-type: Interventional
    phase: Phase 3
    sponsor: National Cancer Institute (NCI)
    url: https://clinicaltrials.gov/study/NCT01272037
    publication-ids:
    - JournalArticle-RxPONDER

cohorts:
  - id: Cohort-MINDACT-Intervention
    study-id: Study-MINDACT
    intervention-group-id: InterventionGroup-MammaOnco-Intervention
  - id: Cohort-MINDACT-Comparator
    study-id: Study-MINDACT
    intervention-group-id: InterventionGroup-MammaOnco-Comparator
  - id: Cohort-RxPONDER-ITT-Intervention
    study-id: Study-RxPONDER
    intervention-group-id: InterventionGroup-MammaOnco-Intervention
  - id: Cohort-RxPONDER-ITT-Comparator
    study-id: Study-RxPONDER
    intervention-group-id: InterventionGroup-MammaOnco-Comparator
  - id: Cohort-RxPONDER-PP-Intervention
    study-id: Study-RxPONDER
    intervention-group-id: InterventionGroup-MammaOnco-Intervention
  - id: Cohort-RxPONDER-PP-Comparator
    study-id: Study-RxPONDER
    intervention-group-id: InterventionGroup-MammaOnco-Comparator

outcome-measurements:
  # MammaPrint
  - id: OutcomeMeasurement-OverallSurvival-TTI-AbsoluteDifference-MammaPrint
    type: absolute difference
    outcome-id: Outcome-Overall-Survival
    cohort-ids: [Cohort-MINDACT-Intervention, Cohort-MINDACT-Comparator]
    value: 1.6
    unit: '%'
    # CI type?
    ci-lower: 1.47
    ci-upper: 4.73
  - id: OutcomeMeasurement-OverallSurvival-TTI-HazardRatio-MammaPrint
    type: hazard ratio
    outcome-id: Outcome-Overall-Survival
    cohort-ids: [Cohort-MINDACT-Intervention, Cohort-MINDACT-Comparator]
    value: 1.36
    ci-lower: 0.74
    ci-upper: 2.50
  - id: OutcomeMeasurement-OverallSurvival-PP-AbsoluteDifference-MammaPrint
    type: absolute difference
    outcome-id: Outcome-Overall-Survival
    cohort-ids: [Cohort-MINDACT-Intervention, Cohort-MINDACT-Comparator]
    value: 0.3
    unit: '%'
    ci-lower: -2.96
    ci-upper: 3.52
  - id: OutcomeMeasurement-OverallSurvival-PP-HazardRatio-MammaPrint
    type: hazard ratio
    outcome-id: Outcome-Overall-Survival
    cohort-ids: [Cohort-MINDACT-Intervention, Cohort-MINDACT-Comparator]
    value: 1.06
    ci-lower: 0.53
    ci-upper: 2.13
  # Oncotype DX
  - id: OutcomeMeasurement-Distant-Relapse-Free-Survival-ITT-HazardRatio-OncotypeDX
    type: hazard ratio
    outcome-id: Outcome-Distant-Relapse-Free-Survival
    cohort-ids: [Cohort-RxPONDER-ITT-Intervention, Cohort-RxPONDER-ITT-Comparator]
    value: 1.05
    ci-lower: 0.81
    ci-upper: 1.37
  - id: OutcomeMeasurement-Distant-Relapse-Free-Survival-ITT-AbsoluteDifference-OncotypeDX
    type: absolute difference
    outcome-id: Outcome-Distant-Relapse-Free-Survival
    cohort-ids: [Cohort-RxPONDER-ITT-Intervention, Cohort-RxPONDER-ITT-Comparator]
    value: 0.1
    unit: '%'
    ci-lower: -0.8
    ci-upper: 1.7
  - id: OutcomeMeasurement-Invasive-Disease-Free-Survival-ITT-HazardRatio-OncotypeDX
    type: hazard ratio
    outcome-id: Outcome-Invasive-Disease-Free-Survival
    cohort-ids: [Cohort-RxPONDER-ITT-Intervention, Cohort-RxPONDER-ITT-Comparator]
    value: 1.04
    ci-lower: 0.8
    ci-upper: 1.30
  - id: OutcomeMeasurement-Invasive-Disease-Free-Survival-ITT-AbsoluteDifference-OncotypeDX
    type: absolute difference
    outcome-id: Outcome-Invasive-Disease-Free-Survival
    cohort-ids: [Cohort-RxPONDER-ITT-Intervention, Cohort-RxPONDER-ITT-Comparator]
    value: 0.6
    unit: '%'
    ci-lower: -1.3
    ci-upper: 2.0
  - id: OutcomeMeasurement-Invasive-Disease-Free-Survival-PP-HazardRatio-OncotypeDX
    type: hazard ratio
    outcome-id: Outcome-Invasive-Disease-Free-Survival
    cohort-ids: [Cohort-RxPONDER-PP-Intervention, Cohort-RxPONDER-PP-Comparator]
    value: 0.97
    ci-lower: 0.77
    ci-upper: 1.22
  - id: OutcomeMeasurement-Invasive-Disease-Free-Survival-PP-AbsoluteDifference-OncotypeDX
    type: absolute difference
    outcome-id: Outcome-Invasive-Disease-Free-Survival
    cohort-ids: [Cohort-RxPONDER-PP-Intervention, Cohort-RxPONDER-PP-Comparator]
    value: -0.3
    unit: '%'
    ci-lower: -2.0
    ci-upper: 2.3

bias:
  - id: BIA-MammaPrint
    title: Budget Impact Analyse voor MammaPrint
    trend-assumption-id: TrendAssumption-MammaOnco
    cost-estimation-ids:
    - CostEstimation-MammaPrint
  - id: BIA-OncotypeDX
    title: Budget Impact Analyse voor Oncotype DX
    trend-assumption-id: TrendAssumption-MammaOnco
    cost-estimation-ids:
    - CostEstimation-OncotypeDX

scenarios:
  - id: Scenario-MammaOnco-Substitution
    title: Substitutie scenario voor MammaPrint en/of Oncotype DX
    description: Dit scenario beschrijft de substitutie van standaardzorg door MammaPrint & Oncotype tests.

trend-assumptions:
  - id: TrendAssumption-MammaOnco
    title: Geschatte trend voor MammaPrint en/of Oncotype DX
    scenario-id: Scenario-MammaOnco-Substitution
    number-of-patients: [ 808 ]
    intervention-market-penetration: [ 1 ]


# Intervention-MammaPrint
# Intervention-OncotypeDX
# Intervention-PostoperativeChemo
# Intervention-MammaPrint-Chemo
# Intervention-OncotypeDX-Chemo
cost-estimations:
  - id: CostEstimation-MammaPrint
    title: Kostenraming voor MammaPrint
    trend-assumption-id: TrendAssumption-MammaOnco
    scenario-id: Scenario-MammaOnco-Substitution
    observation-groups:
      - type: Current
        intervention-ids: [Intervention-PostoperativeChemo]
        number-of-patients: [ 808 ]
        total-costs: [ 12_773_672 ] # 15_809 * 808
      - type: Substitution
        intervention-ids: [ Intervention-MammaPrint ]
        number-of-patients: [ 808 ]
        total-costs: [ 2_625_192 ] # 3_249 * 808
      - type: Substitution
        intervention-ids: [ Intervention-PostoperativeChemo ]
        number-of-patients: [ 373 ] 
        total-costs: [ 5_896_757 ] # 15_809 * 373 = 5_896_757
      - type: Total
        intervention-ids: [ Intervention-MammaPrint-Chemo, Intervention-PostoperativeChemo ]
        number-of-patients: [ 808 ]
        total-costs: [ 8_521_949 ] # 2_625_192 + 5_896_757
      - type: Additional
        intervention-ids: [ Intervention-MammaPrint-Chemo ]
        number-of-patients: [ 808 ]
        total-costs: [ -4_251_723 ] # 8_521_949 - 12_773_672
  - id: CostEstimation-OncotypeDX
    title: Kostenraming voor Oncotype DX
    trend-assumption-id: TrendAssumption-MammaOnco
    scenario-id: Scenario-MammaOnco-Substitution
    observation-groups:
      - type: Current
        intervention-ids: [Intervention-PostoperativeChemo]
        number-of-patients: [ 808 ]
        total-costs: [ 12_773_672 ] # 15809 * 808
      - type: Substitution
        intervention-ids: [ Intervention-OncotypeDX ]
        number-of-patients: [ 808 ]
        total-costs: [ 3_904_256 ] # 4_832 * 808
      - type: Substitution
        intervention-ids: [ Intervention-PostoperativeChemo ]
        number-of-patients: [ 373 ] 
        total-costs: [ 5_896_757 ] # 15809 * 373 = 5_896_757
      - type: Total
        intervention-ids: [ Intervention-OncotypeDX-Chemo, Intervention-PostoperativeChemo ]
        number-of-patients: [ 808 ]
        total-costs: [ 9_801_013 ] # 3_904_256 + 5_896_757
      - type: Additional
        intervention-ids: [ Intervention-OncotypeDX ]
        number-of-patients: [ 808 ]
        total-costs: [ -2_972_659 ] # 9_801_013 - 12_773_672


appropriate-use:
  id: AU-MammaOnco
  title: Gepast gebruik afspraken MammaPrint en Oncotype DX
  date: 2023-09-26
  agreements:
  - description: Uitgebreide patiëntinformatie en richtlijnen voor professionals over bij welke subgroep van vrouwen deze genexpressietesten van toegevoegde waarde zou kunnen zijn en wat de implicaties zijn, zodat de vrouw in overleg met haar arts een weloverwogen besluit kan nemen of inzet van een genexpressietest in het individuele geval van toegevoegde waarde is (samen beslissen). De BVN heeft toegezegd in afstemming met Patiëntfederatie Nederland de bestaande patiënteninformatie te updaten vóór maart 2024. 
  - description: Revisie van de huidige richtlijn waarin de resultaten van de RxPonder-studie, TailorX-studie (Oncotype DX®) en 8-jaars resultaten van de MINDACT-studie (MammaPrint®) zijn opgenomen. De NABON heeft toegezegd dat de module wordt geprioriteerd voor de volgende jaarlijkse cyclus. Omdat het updaten van richtlijnen niet op korte termijn gerealiseerd is, zal de beroepsgroep een standpunt publiceren over MammaPrint en Oncotype DX op haar website.
  - description: Inzet van genexpressietesten alleen als add-on-test aan de standaard risicoschatting, indien op basis van de standaard risicoschatting twijfel bestaat over de meerwaarde van adjuvante chemotherapie. Het is niet de bedoeling om de genexpressietest in plaats van de standaard risicoschatting in te zetten. 
  - description: Vanwege het ontbreken van de directe vergelijking weten we nu niet welke test de meeste gezondheidswinst voor de patiënt oplevert. De beroepsgroep spant zich in om hier inzicht in te krijgen door het bijhouden van de internationale literatuur en/of uitkomsten uit registraties. Het Zorginstituut zal jaarlijks navraag doen bij de beroepsgroep of er nieuwe publicaties verschenen zijn. 
  - description: Inzet van één van de testen per tumor (en niet beide testen). Dat de twee testen niet uitwisselbaar zijn zou er mogelijk toe kunnen leiden dat zorgprofessionals en patiënten geneigd zijn om beide testen bij één patiënt af te nemen, om alleen bij concordante uitslagen (dezelfde uitslagen) een patiënt te informeren over het advies over wel of geen adjuvante chemotherapie. Het is echter niet onderzocht of het klinisch nuttig en doelmatig is om beide testen bij één patiënt af te nemen. Het Zorginstituut is daarom van mening dat de inzet van genexpressie testen beperkt moet blijven tot één van de testen per tumor.  
  - description: Het Zorginstituut zal monitoren en evalueren of er sprake is van gepast gebruik van de testen. In nauwe afstemming met de beroepsgroep worden hiervoor eindpunten gedefinieerd.

